A preferable signature of gut microbiota and bile acids predicted better outcomes of unresectable hepatocellular carcinoma to immune checkpoint inhibitors

被引：0
|
作者：
Lee, Pei-Chang [1 ]
Wu, Chijung [1 ]
Hung, Ya-Wen [1 ]
Lee, ChiehJu [1 ]
Chi, Chen-Ta [1 ]
Lee, I-Cheng [1 ]
Luo, Jiing-Chyuan [1 ]
Hou, Ming-Chih [1 ]
Huang, Yi-Hsiang [1 ]
机构：
[1] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Dept Med, Taipei, Taiwan
来源：
JOURNAL OF HEPATOLOGY | 2022年 / 77卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OS160
引用
收藏
页码：S109 / S110
页数：2
相关论文
共 50 条
  • [41] Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma
    Hu, Yue
    Pan, Tao
    Cai, Xi
    He, Quan-Sheng
    Zheng, Yu-Bao
    Huang, Ming-Sheng
    Jiang, Zai-Bo
    Chen, Jun-Wei
    Wu, Chun
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (04) : 1837 - +
  • [42] Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re-analysis of a meta-analysis
    Zhou, Shouhao
    Shen, Chan
    JGH OPEN, 2023, 7 (02): : 163 - 164
  • [43] Deep learning of pretreatment multiphase CT images for predicting response to lenvatinib and immune checkpoint inhibitors in unresectable hepatocellular carcinoma
    Liao, Nan-Qing
    Deng, Zhu-Jian
    Wei, Wei
    Lu, Jia-Hui
    Li, Min-Jun
    Ma, Liang
    Chen, Qing-Feng
    Zhong, Jian-Hong
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2024, 24 : 247 - 257
  • [44] Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues
    Yang, Shiye
    Liang, Huoqi
    Li, Xing
    Qian, Jiayi
    Ming, Zhibing
    HEPATOLOGY INTERNATIONAL, 2024, 18 (04) : 1336 - 1337
  • [45] A novel immune checkpoint-related gene signature for hepatocellular carcinoma to predict clinical outcomes and therapeutic response
    Tian, Siyuan
    Hu, Yinan
    Yang, Chunmei
    Yu, Jiahao
    Liu, Jingyi
    Xuan, Guoyun
    Liu, Yansheng
    Sun, Keshuai
    Zhang, Miao
    Ma, Shuoyi
    Shang, Yulong
    Zhou, Xia
    Han, Ying
    MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2022, 19 (05) : 4719 - 4736
  • [46] Real-world experience and outcomes of immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC)
    Paul, Samuel
    Min, Eric
    Benson, Katherine K.
    Xu, Menglin
    Noonan, Anne M.
    Mittra, Arjun
    Malalur, Pannaga G.
    Roychowdhury, Sameek
    Jin, Ning
    Hays, John L.
    Elkhatib, Rifat T.
    Rahman, Shafia
    Miller, Eric David
    Pardo, Dayssy Alexandra Diaz
    Manne, Ashish
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma.
    Cortellini, Alessio
    Marron, Thomas Urban
    Mishra-Kalyani, Pallavi Shruti
    Gong, Yutao
    Saeed, Anwaar
    Jun, Tomi
    Dharmapuri, Sirish
    Naqash, Abdul Rafeh
    Khan, Uqba
    Kaseb, Ahmed Omar
    Huang, Yi-Hsiang
    Ang, Celina
    Schneider, Julie A.
    Pillai, Anjana
    Rimassa, Lorenza
    Pazdur, Richard
    Theoret, Marc Robert
    Lemery, Steven
    Pelosof, Lorraine Cheryl
    Pinato, David James
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] A Model of Basement Membrane-Associated Gene Signature Predicts Liver Hepatocellular Carcinoma Response to Immune Checkpoint Inhibitors
    Shen, Jiajia
    Wei, Zhihong
    Lv, Lizhi
    He, Jingxiong
    Du, Suming
    Wang, Fang
    Wang, Ye
    Ni, Lin
    Zhang, Xiaojin
    Pan, Fan
    MEDIATORS OF INFLAMMATION, 2023, 2023
  • [49] Changes in Serum Interleukin-8 Levels Predict Response to Immune Checkpoint Inhibitors Immunotherapy in Unresectable Hepatocellular Carcinoma Patients
    Zhang, Jiao
    Yin, Yi
    Tang, Jiliang
    Zhang, Yingrong
    Tian, Yanan
    Sun, Fengkai
    JOURNAL OF INFLAMMATION RESEARCH, 2024, 17 : 3397 - 3406
  • [50] Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study
    Jiang, Nan
    Zhong, Binyan
    Huang, Jintao
    Li, Wanci
    Zhang, Shuai
    Zhu, Xiaoli
    Ni, Caifang
    Shen, Jian
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345